WinstonWınston
Back
Stock

Viridian Therapeutics

VRDN
31
Biotechnology · Healthcare
Also trades as: 0K1R.L GBP 0.22 (-2.40%)
Price
$22.37
-0.45 (-1.97%)
pre-market:$20.11-10.10%
Market Cap
$2.53B
Exchange
NASDAQ
Winston Score
31
Winston is serious
Below-average fundamentals — multiple weak pillars.
Data as of Oct 24, 2026 · filings through Jun 30, 2026

§How the score breaks down

Quality
Mixed
10/30
Growth
Mixed
7/20
Cash Flow
Weak
0/10
Stability
Mixed
4/10
Valuation
Data not available
0/10
Ownership
Good
8/15
Dividends
Not counted
n/a

29 of 95 counted points = Winston Score 31. Pillars marked n/a do not apply to this company and are left out of the total.

Track this stock — start free trial

Share count rising — dilution

+611.5% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 11.9M (2021) → 84.8M (2025)

§Winston Score History

The full picture

Viridian Therapeutics is a biotechnology company that develops medicines for serious diseases caused by overactive immune systems. Its main focus is thyroid eye disease (TED), a condition where the immune system attacks tissue around the eyes, causing swelling and vision problems. The company's lead drug candidate, VRDN-001, targets a protein called IGF-1R, which plays a key role in driving TED.

Viridian makes money by developing and eventually selling prescription drugs, though it currently has no approved products generating meaningful revenue — the near-100% gross margin reflects minimal cost of goods on small research-related income. The company operates primarily in the United States and is in the clinical-stage phase, meaning it spends heavily on trials while earning little, which explains the deeply negative operating margin. Its main growth driver is winning regulatory approval for its TED treatments, but its biggest risk is competition from Amgen's already-approved teprotumumab (Tepezza), which dominates the TED market today.

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+278.7% YoY

YoY Growth Rate

Strong revenue growth

Reported EPS Growth

+14.6% YoY

Quarterly reporting periods ended:

30 Jun 2025: $-1.23

30 Jun 2026: $-1.05

Reported/statutory EPS, not adjusted or underlying earnings. One-off items can affect this figure. Provider rounding can affect the growth rate.

YoY Growth Rate

Reported EPS increased year over year

R&D Spend

$339M/ year

↑ Rising (+42% vs prior year)

478.4% of revenue

26.6x the sector average (18%)

Investing heavily in future products and technology

Insider Activity

7.2%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

~2 years

$982M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

$982M cash & investments at current burn rate

Strong grower

Viridian Therapeutics is growing revenue at 279% year-over-year. The Winston Score penalises unprofitable companies, but revenue at this pace tells a different story — this is a company still in "build mode."

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale
Gross Margin
100.0%
Premium pricing power — 100.0% gross margin
Profit after running costs
Operating Margin
-44460.6%
Losing money on operations — -44460.6%
Return on the money invested
ROCE
-44.8%
Weak — -44.8% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth
Sales YoY
>+1,000%
Fast-growing sales (>+1,000% YoY)
Profit growth
EPS YoY
N/A
—
Data not available
How steady the profit is
EPS Consistency
3/8 quarters
Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash
Cash Conversion
N/A
—
Data not available
Spare cash per sale
FCF Margin
-471.0%
Burning cash (-471.0%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns
Debt / Equity
0.37
Conservative — low debt load (0.37)
Covers its interest
Interest Cover
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit
P/E Ratio (TTM)
N/M
—
Negative earnings — P/E not meaningful
Cheaper or dearer next year
P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial